The Level Ena subscription-based marketing plan delivers social media and blog content directly to your inbox at industry recommended frequencies. All you need to do is post on your specified channel. When subscribing to the plan you will need to select from the following channels:
One channel is included in the Level Ena subscription plan, but more can be added during the registration process at an additional cost. After selecting your desired social media channels, you will then need to determine the target audience. Kinetogram is experienced in addressing the following markets:
- Infectious diseases
- Inherited disease
- Rare disease
The way you interact with a clinical audience is very different from that of a research scientist. It is important to use the correct language for a clinical customer and follow Regulatory Guidelines. Kinetogram has experience in the following areas:
- Research Use Only (RUO)
- Laboratory Developed Tests (LTDs)
The Level Ena subscription plan also includes a weekly 300-word blog for your market focus. If content generated will be applied in the clinical market, regulatory clearance from your company will need to be obtained before posting. All other content is ready to post immediately.
Digital marketing can be measured to monitor audience impact and determine if budgets are being spent effectively. Therefore, it is important to establish Key Performance Indicators (KPIs) prior to implementing digital marketing activities. Through KPIs it is possible to track messaging, content quality and customer sentiment. Each week a report will be generated and delivered to your marketing team. You will be asked to determine KPIs associated with your subscription-based marketing level during the initial consultation period.
After an initial 1-hour consultation Kinetogram will help you determine the best channels to reach your audience and provide a guideline as to the frequency of your social media posts. There is a fine balance between infrequent postings and bombarding your audience which can cause unsubscribes.
There are no reviews yet.